Key facts
- Notable investors include Vanderbilt University, Zubi Capital, StartUp Health.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Abvance Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Abvance Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abvance Therapeutics
Developer of a glucagon-based insulin therapy designed to improve glycemic control while reducing the risk of hypoglycemia. The company's technology offers a titratable combination of insulin and glucagon, integrating into current diabetes care without requiring new devices or behavioral changes, enabling people with diabetes to manage their condition and live with less daily fear.
- Sector
- Healthcare
- HQ
- Reno, NV, United States
- Founded
- 2016
- Employees
- 9
- Website
- abvancetherapeutics.com/
- Ownership
- Privately Held (backing)
Abvance Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abvance Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abvance Therapeutics in its N-PORT filings yet. We sweep new filings monthly.